The new anti-wrinkle facial filler Dysport, which could be used as an alternative to Botox, noticeably reduced frown lines between the eyes, according to users and independent reviewers in a study involving plastic surgeons at UT Southwestern Medical Center.
Get the full story...
Ipsen (Paris:IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Reloxin® (botulinum toxin of type A) Biologics License Application (BLA) in aesthetic indications (glabellar lines) has been extended to April 13, 2009.
Get the full story...
The current battle between the makers of anti-wrinkle products - widely compared with the Coke and Pepsi struggle for superiority - is receiving an injection of scientific understanding with the release of a new study from the University of Michigan Health System.
Read the full story
